Allarity Therapeutics (ALLR) Accumulated Expenses (2020 - 2026)

Allarity Therapeutics (ALLR) has 7 years of Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Accumulated Expenses fell 58.46% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 58.46% YoY) and the FY2025 annual result came in at $2.7 million, down 49.03% from the prior year.
• Accumulated Expenses fell to $2.2 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.3 million in Q1 2025 to a low of $49000.0 in Q3 2022.
• A 5-year average of $2.0 million and a median of $1.9 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 98.34% — and 2023, when it surged 2930.61%.
• Tracing ALLR's Accumulated Expenses over 5 years: stood at $1.9 million in 2022, then sank by 79.1% to $398000.0 in 2023, then soared by 1214.57% to $5.2 million in 2024, then slumped by 49.03% to $2.7 million in 2025, then declined by 17.85% to $2.2 million in 2026.
• The last three Accumulated Expenses figures came in at $2.2 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.